Cited by 286Smoking Behavior and CessationPharmacovigilance and Adverse Drug ReactionsCardiac Health and Mental Health

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

Open access

Singh, S., Loke, Y. K., Spangler, J. G., Furberg, C. D.·2011·Canadian Medical Association Journal

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: There have been postmarketing reports of adverse cardiovascular events associated with the use of varenicline, a widely used smoking cessation drug. We conducted a systematic review and meta-analysis of randomized controlled trials to ascertain the serious adverse cardiovascular effects of varenicline compared with placebo among tobacco users. METHODS: We searched MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, websites of regulatory authorities and registries of clinical trials, with no date or language restrictions, through September 2010 (updated March 2011) for published and unpublished studies. We selected double-blind randomized controlled trials of at least one week's duration involving smokers or people who used smokeless tobacco that reported on cardiovascular events (ischemia, arrhythmia, congestive heart failure, sudden death or cardiovascular-related death) as serious adverse events asociated with the use of varenicline. RESULTS: We analyzed data from 14 double-blind randomized controlled trials involving 8216 participants. The trials ranged in duration from 7 to 52 weeks. Varenicline was associated with a significantly increased risk of serious adverse cardiovascular events compared with placebo (1.06% [52/4908] in varenicline group v. 0.82% [27/3308] in placebo group; Peto odds ratio [OR] 1.72, 95% confidence interval [CI] 1.09-2.71; I(2) = 0%). The results of various sensitivity analyses were consistent with those of the main analysis, and a funnel plot showed no publication bias. There were too few deaths to allow meaningful comparisons of mortality. INTERPRETATION: Our meta-analysis raises safety concerns about the potential for an increased risk of serious adverse cardiovascular events associated with the use of varenicline among tobacco users.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1503/cmaj.110218

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Gonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361
The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality: A Randomized Clinical Trial
Anthonisen, N. R., Skeans, M. A., Wise, R. A., Manfreda, J., Kanner, R. E., Connett, J. E., & for the Lung Health Study Research Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-4-200502150-00005 · Cited by 1,237
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
Nicotine receptor partial agonists for smoking cessation
Hey, K., Lancaster, T., & Bala, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103 · Cited by 866
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Effect of Maintenance Therapy With Varenicline on Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Tonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558

Flagged first, then by citations

Show all 33 references

Research works printed but not linked: 2

Josefberg H. Approval package for: application number NDA 21- 928 [clinical safety review: varenicline tartrate]. Rockville (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2006. p. 277, 402. Available: www .accessdata .fda .gov /drugsatfda _docs /nda /2006 /021928 _s000 _Chantix _MedR .pdf (ac cessed 2011 Apr. 14).
Montastruc G, Degand B, Montastruc JL, et al. Cardiac arrest with varenicline: a case report [article in French]. Therapie 2009; 64: 65-6.

Sorted by citations

Items 201–285 of 285

Varenicline and evaluated outcomes in smoking cessation programmes
Santus, P., Bassi, L., Airoldi, A., Giovannelli, F., & Radovanovic, D. (2015) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2013.105 · Cited by 2
Review: Varenicline is better than bupropion but not nicotine patch for smoking abstinence in adults
Prochazka, A. V., & Caverly, T. J. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-6-201209180-02007 · Cited by 2
Tobacco Cessation Approaches and Impact on CVD
Pillai, H. S., & Ganapathi, S. (2012) · Global Heart · doi:10.1016/j.gheart.2012.06.001 · Cited by 2
Europejskie wytyczne dotycza̧ce zapobiegania chorobom serca i naczyń w praktyce klinicznej na 2012 rok
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · Ghent University Academic Bibliography (Ghent University) · Cited by 2
Pharmacotherapy for Smoking Cessation in Cardiovascular Patients
Kim, S.-H., & Cho, H. (2015) · Journal of the Korean Society for Research on Nicotine and Tobacco · doi:10.25055/jksrnt.2015.6.2.71 · Cited by 2
Evaluation of reproductive and renal toxicity of varenicline in male rats.
Oğuz, F., Beytur, A., Taşlıdere, E., Parlakpınar, H., Oğuz, H. K., Polat, A., Topçu, İ., Vardı, N., & Selçuk, E. B. (2019) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2019.13986 · Cited by 2
Drug Addiction
Ellenbroek, B. A., & Youn, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801657-2.00006-9 · Cited by 2
The utility of the self‐controlled study design for pharmacoepidemiological studies without an active comparator medication using a medical information database: An application to assess the risk of varenicline on cardiovascular outcomes
Yokoyama, R., Takeuchi, Y., Kumamaru, H., & Matsuyama, Y. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5634 · Cited by 2
Extended varenicline treatment in a severe cardiopathic cigarette smoker: a case report
Munarini, E., Marabelli, C., Pozzi, P., & Boffi, R. (2015) · Journal of Medical Case Reports · doi:10.1186/1752-1947-9-29 · Cited by 2
Therapeutic concentrations of varenicline increases exocytotic release of catecholamines from human and rat adrenal chromaffin cells in the presence of nicotine
Jiménez‐Pompa, A., Sanz‐Lázaro, S., Hone, A. J., Rueda‐Ruzafa, L., Medina‐Polo, J., Enguita, C. G., Blázquez, J., Rı́os, C. D. L., McIntosh, J. M., & Albillos, A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108632 · Cited by 2
Choice of summary statistics: relative and absolute measures
Prochaska, J. J., & Hilton, J. F. (2013) · BMJ · doi:10.1136/bmj.f1092 · Cited by 2
Flaws in analysis lead to misleading conclusions about varenicline's safety in smoking cessation
Singh, S., & Loke, Y. K. (2012) · BMJ · doi:10.1136/bmj.e3873 · Cited by 2
Self-citation
Authors' response
Singh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.111-2072 · Cited by 2
Self-citation
NetMedGPT - A network medicine foundation model for extensive disease mechanism mining and drug repurposingPreprint
Firoozbakht, F., Süwer, S., Elkjaer, M. L., Handy, D. E., Maier, A., Li, J., Lancashire, L., Loscalzo, J., & Baumbach, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.04.697552 · Cited by 2
The Effect of Varenicline on Smoking Cessation in Hospitalized Patients: A Systematic Review and Meta-Analysis
Aryanpur, M., Ghorbani, R., Rashno, S., Heydari, G., Dizaji, M. K., Hessami, Z., & Ghorbani, N. (2024) · Addiction and Health · doi:10.34172/ahj.2024.1328 · Cited by 1
Design Strategy for a Smoking Cessation Trial of Survival
Shuster, J. J. (2013) · Clinical and Translational Science · doi:10.1111/cts.12124 · Cited by 1
Tratamiento del tabaquismo en pacientes con enfermedad pulmonar obstructiva crónica
Sergio Bello, S., Haydée Chamorro, R., & Andrea Barrientos, R. (2013) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482013000100004 · Cited by 1
Short-term effects of varenicline therapy on homogeneity of heart rate, atrioventricular conduction and ventricular repolarization
KaraveliogAAlu, Y., & Karapınar, H. (2015) · Current research. Cardiology · doi:10.4172/2368-0512.1000033 · Cited by 1
Varenicline for 4 weeks prior to target quit date reduces prequit date smoking and increases 12-week abstinence
Garrison, G. D. (2011) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed.2011.100147 · Cited by 1
Cardiovascular Safety Warnings and the Prescribing of Varenicline
Filion, K. B., Eberg, M., & Azoulay, L. (2016) · Epidemiology · doi:10.1097/ede.0000000000000492 · Cited by 1
New Insight into Alcohol and Nicotine Addiction
Vitali, M., Battagliese, G., & Ceccanti, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800634-4.00085-8 · Cited by 1
NICOTINE REPLACEMENT THERAPY OF THE TOBACCO ADDICTION IN PREVENTION OF CARDIORESPIRATORY DISEASES
Gambaryan, M. G. (2013) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2013-9-3-280-286 · Cited by 1
Psychopharmacological management of schizophrenia
Castle, D. J., Tran, N., & Alderton, D. (2012) · CRC Press eBooks · doi:10.3109/9781842145357.001 · Cited by 1
Varenicline increased smoking cessation at 24 weeks in patients hospitalized with ACS and motivated to quit
Prochazka, A. V. (2016) · Annals of Internal Medicine · doi:10.7326/acpjc-2016-164-6-043 · Cited by 1
How to Choose the Medications for Treating Nicotine Dependence?
Kim, Y.-H., Paek, Y., & Lee, E.-Y. (2015) · Journal of the Korean Society for Research on Nicotine and Tobacco · doi:10.25055/jksrnt.2015.6.2.65 · Cited by 1
Identification of the most effective pharmaceutical products for smoking cessation: A literature review
Ghamri, R. (2018) · Journal of Substance Use · doi:10.1080/14659891.2018.1489010 · Cited by 1
Tobacco
Basu, D., Mitra, S., & Vadivelu, N. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1951-2_9 · Cited by 1
Maßnahmen zur Tabakprävention
Hanewinkel, R., Isensee, B., & Morgenstern, M. (2012) · Der Pneumologe · doi:10.1007/s10405-011-0557-8 · Cited by 1
Anosmia due to Varenicline; A case report
Daghistani, K. J. (2014) · Online Journal of Otolaryngology · Cited by 1
Elimination of Cigarette Smoke-derived Acetaldehyde in Saliva by Slow-release L-Cysteine Lozenge Is a Potential New Method to Assist Smoking Cessation. A Randomised, Double-blind, Placebo-controlled Intervention.
Syrjänen, K. J., Salminen, J., Aresvuo, U., Hendolin, P., Paloheimo, L. I., Eklund, C., Salaspuro, M. P., & Suovaniemi, O. (2016) · PubMed · Cited by 2
Management of Angina
Kaski, J. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-41180-4_6 · Cited by 1
Smoking and Vaping
Luepker, R. V. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_8 · Cited by 1
Varenicline for Smoking Reduction Prior to Cessation
Robey, R. B., Block, C. A., & O’Rourke, D. J. (2015) · JAMA · doi:10.1001/jama.2015.4978 · Cited by 1
Cardiovascular and neuropsychiatric risks of varenicline
Fidler, L. M., Anand, A., & Stanbrook, M. B. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00523-8 · Cited by 1
Smoking and Coronary Artery Disease.
Saku, K., Zhang, B., Noda, K., & Tsukahara, H. (2012) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.101.779 · Cited by 1
Tratamiento del tabaquismo
Torracchi, A. M., Martı́nez, L., & Barrueco, M. (2013) · Actualidad en farmacología y terapéutica
EFFECT OF SMOKING AND CESSATION IN HIV-INFECTED PEOPLE
Cui, Q. (2011) · MacSphere (McMaster University) · doi:10.71548/18671
Qué deben saber los cardiólogos del tratamiento farmacológico para dejar de fumar
Zabert, G. E., Ruiz, C. J., & Zabert, I. (2011) · Redalyc (Universidad Autónoma del Estado de México)
Vareniclin – Erhöhtes kardiovaskuläres Risiko bei der Raucherentwöhnung?
Dewenter, M., & El‐Armouche, A. (2012) · Der Kardiologe · doi:10.1007/s12181-012-0425-8
Pharmacological therapies in smoking cessation: an evidence-based update
Allam, J. S., & Ochoa, C. (2015) · Current Pulmonology Reports · doi:10.1007/s13665-015-0125-5
The Risk of Adverse Cardiovascular Events From Varenicline Balanced Against the Benefits in Mortality From Smoking Cessation
Kistler, C. E., & Goldstein, A. O. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts028
Transdermal Nicotine Replacement Therapy Safety in Patients with Cardiovascular Disease
Galen, K., Lurk, K. M., & Smith, A. (2011) · Hospital Pharmacy · doi:10.1310/hpj4610-769
Authors' reply to Singh and Loke
Hilton, J. F., & Prochaska, J. J. (2012) · BMJ · doi:10.1136/bmj.e4033
The pain of giving up smoking
Kozor, R., & Bhindi, R. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.10.083
Tratamiento de los factores de riesgo vascular y objetivos terapéuticos
Arriaga, B. A., del Hoyo, J. C., García, M. P. G., & Calvo, J. I. P. (2013) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(13)70638-3
Review: Nicotine replacement therapy increases CVD events; bupropion and varenicline do not
Rowland, K. (2014) · Annals of Internal Medicine · doi:10.7326/0003-4819-160-8-201404150-02002
Srce i krvni Sudovi
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true?
Nielen, J. T. H., & Burden, A. M. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00467-1
VARENICLINE IN PATIENTS WITH CARDIOVASCULAR DISEASES – FRIEND OR ENEMY?
Lukina, Y. V., & Martsevich, S. Y. (2013) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2013-9-4-455-458
testosterone, cardiovascular, men, trial
Xu, L., Freeman, G. H., Cowling, B. J., & Schooling, M. (2013) · CUNY Academic Works (City University of New York)
PURLs: Counseling is a must with this smoking cessation aid.
Stephens, L. A., & Stevermer, J. (2012) · PubMed Central
Sons of a lesser god: smoking cessation treatment in patients with mental illness
Lugoboni, F., Faccini, M., Casari, R., Guadagnini, P., & Gamba, F. (2011)
Eficacia y seguridad del uso de medicamentos para la cesación de la adicción al tabaco: revisión de guías de práctica clínica Efficacy and safety of medication use for the cessation of tobacco addiction: A review of Clinical Practice Guidelines
Cañas, A., Becerra, N., Murillo, R., Páez, N., & Mosquera, C. (2014)
Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica (versión 2012) Quinto Grupo de Trabajo de la Sociedad Europea de Cardiología y otras Sociedades sobre la Prevención de la Enfermedad Cardiovascular en la Práctica Clínica (constituido por representantes de nueve sociedades y expertos invitados)
Perk, J. (2012)
Effects of smoking and smoking cessation on mental disorders
Noda, T. (2016) · The Japanese Journal of Health Psychology · doi:10.11560/jahp.28.special_issue_129
Wytyczne ESC dotyczące postępowania w stabilnej chorobie wieńcowej w 2013 roku Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw postępowania w stabilnej chorobie wieńcowej
Sechtem, U. P., & Krankenhaus, R. B. (2013)
A Discussion about Modalities of Smoking Cessation in Perioperative Phase for Addicts: A Review Article
Kar, S. K. (2014) · Journal of Addiction Medicine and Therapeutic Science · doi:10.17352/2455-3484.000002
Systematic Review/Meta-analysis Bupropion for Smoking Cessation in Patients Hospitalized With Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Grandi, S. M., Shimony, A., & Eisenberg, M. J. (2013)
Treating Tobacco Use in Clinical Practice
Carroll, A. J., Veluz‐Wilkins, A. K., & Hitsman, B. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-24687-1_15
Management of smoking dependence
(2012) · Journal of Functional Ventilation and Pulmonology · doi:10.12699/jfvp.3.9.2012.7
Exposição prolongada de ratos a vareniclina: avaliação comportamental, níveis de neurotransmissores cerebrais e estudo bioquímico e anatomopatológico
Zaccarelli‐Magalhães, J. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.10.2017.tde-20032017-141445
Ensayo controlado citisina versus placebo para la cesación del tabaquismo
Serna, C. P. Z., & Cañas, A. (2016) · Revista Colombiana de Neumología · doi:10.30789/rcneumologia.v26.n4.2014.10
Role of the Cannabinoid System in Modulating the Reinforcing and Relapse Related Properties of Nicotine in Rats
Gamaleddin, I. (2013) · TSpace (University of Toronto)
Medical Therapy of Peripheral Artery Disease
Joseph, L., & Kim, E. (2017) · Wiley eBooks · doi:10.1002/9781118775998.ch6
Maßnahmen zur Tabakprävention
Loddenkemper, R. (2012)
Pharmacotherapy in Effort to Quit Smoking
Ekawati, D., Radi, B., & Taufik, F. F. (2016) · Indonesian Journal of Cardiology · doi:10.30701/ijc.v36i4.505
The Implication of the Corticotropin Releasing Factor in Nicotine Dependence and Significance for Pharmacotherapy in Smoking Cessation
Karasavva, V. (2019) · doi:10.22186/jyi.36.3.36-43
DTB Select: 8 | September 2011
(2011) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2011.02.0052
Varenicline Increases Risk of Adverse Cardiovascular Events
(2012) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)30149-8
Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkankungen, 9. Auflage
(2013) · Elsevier eBooks · doi:10.1016/b978-3-437-24905-1.16001-0
Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage
(2017) · Elsevier eBooks · doi:10.1016/b978-3-437-24909-9.16001-3
Editorial Comment
Knopf, J. K., & Messing, E. M. (2011) · Urology · doi:10.1016/j.urology.2011.07.1421
Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage
(2019) · Elsevier eBooks · doi:10.1016/b978-3-437-24911-2.16001-8
Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 10. Auflage
(2014) · Elsevier eBooks · doi:10.1016/b978-3-437-24906-8.16001-6
The withdrawal of drugs from the market as a result of post-authorisation pharmacovigilance
Dobrek, Ł. (2022) · Farmacja Polska · doi:10.32383/farmpol/153052
ПОШИРЕНІСТЬ ЗАХВОРЮВАНЬ СЕРЦЕВО-СУДИННОЇ СИСТЕМИ СЕРЕД НАСЕЛЕННЯ ОСТРОЗЬКОГО РАЙОНУ У 2009–2019 РР., РОЗРОБЛЕННЯ ПРОФІЛАКТИЧНИХ ЗАХОДІВ
Kushniruk, H. A. (2022) · Public Health Journal · doi:10.32782/pub.health.2022.1.5
Leserbriefe
(2017) · Zeitschrift für Allgemeinmedizin · doi:10.1007/bf03652892
Tobacco Cessation
Hoffman, A. C., & King, C. (2024) · The American Pharmacists Association eBooks · doi:10.21019/aphaotc-other.tobacco-cessation
Literaturverzeichnis zu Voderholzer (Hrsg.): Therapie psychischer Erkrankungen, 20. Auflage
(2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21224-6.00055-4
Lifestyle Management of Hypertension and Type 2 Diabetes
Kim, J. H. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.3.120
Medications for Smoking Cessation
Clements, J. N. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch23
Addition of Bupropion or Varenicline to Nicotine Replacement Therapy After Acute Coronary Syndrome: A Propensity-Matched Real-World AnalysisPreprint
Qadeer, A., Gohar, N., Maniyar, P., Juarez, L. M., Shafi, N., Krishna, S. R. G., Mortada, I., Pack, Q. R., Jneid, H. M., & Gaalema, D. E. (2026) · medRxiv · doi:10.64898/2026.04.21.26351432
Comparison of clinical outcomes between different smoking cessation therapies in patients with chronic kidney diseasePreprint
Zheng, J.-Q., Hou, Y., Lu, C., Wang, J., Yang, H.-C., Sandar, T. T., Zheng, C., & Lu, K. (2026) · Research Square · doi:10.21203/rs.3.rs-9531023/v1
BindingDB Entry 50043556: TBA
BindingDB (2014) · UC San Diego · doi:10.7270/q2jw8gbv
BindingDB Entry 50044461: Identification of a new selective dopamine D4 receptor ligand.
BindingDB (2015) · UC San Diego · doi:10.7270/q25140rw

Authors: Singh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D.
Affiliations: Johns Hopkins University (US)
ORCID: Singh, S.
Loke, Y. K.
Spangler, J. G.
Venue: Canadian Medical Association Journal
Publisher: CMA Joule Inc.
Published: 2011-07-04
Volume: 183
Issue: 12
Pages: 1359-1366
ISSN: 0820-3946 (ISSN-L)
1488-2329
DOI: 10.1503/cmaj.110218
PMC: PMC3168618
OpenAlex: W2160161905
Cited by: 286
References: 33
Citations by year: 2026: 3 · 2025: 4 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 12 · 2017: 18 · 2016: 23 · 2015: 29 · 2014: 31 · 2013: 52 · 2012: 56
FWCI: 5.63
Type: journal article
Language: en
Open access: gold
doi.org
Locations: Canadian Medical Association Journal (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UEA Digital Repository (University of East Anglia) (submittedVersion)
Funders: National Center for Research Resources (KL2RR025006)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Keywords: varenicline, cardiovascular adverse events, smoking cessation, nicotine replacement therapy, myocardial ischemia, cardiac arrhythmias, congestive heart failure, sudden death, tobacco users, drug safety
MeSH terms: Varenicline, Benzazepines, Cardiovascular Diseases, Humans, Product Surveillance, Postmarketing, Quinoxalines, Risk, Randomized Controlled Trials as Topic, Nicotinic Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks